<DOC>
	<DOCNO>NCT00261092</DOCNO>
	<brief_summary>Primary objective : - To evaluate overall response rate ( base RECIST criterion ) Secondary objective : - To evaluate time progression , clinical benefit , quality life safety</brief_summary>
	<brief_title>GEMOX : Oxaliplatin Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven adenocarcinoma pancreas Metastatic locally advance , non resectable disease ( Non resectable disease determine investigator clinical data ) Unidimensionally measurable disease define RECIST ( primary secondary tumor &gt; 2cm use conventional CT scan ≥1cm spiral CT scan ) No previous chemo radiotherapy , postoperative radiotherapy adjuvant therapy nontarget lesion permit Karnofsky Performance Status ( KPS ) ≥60 No known Central Nervous System metastases No sensory neuropathy inclusion Biological hematological evaluation &lt; 2 week prior treatment administration : Neutrophils ≥ 1500/ mm3 Platelets ≥ 100,000/mm3 Alkaline phosphatase &lt; 5X ULN ( upper Limits Normal ) Bilirubin &lt; 1.5X ULN SGOT , SGPT &lt; 2.5 X ULN liver metastasis SGOT , SGPT &lt; 5 X ULN liver metastasis Creatinine &lt; 1.5 X ULN Baseline imaging ( CT scan Magnetic Resonance Imaging ) &lt; 3 week treatment administration Men woman fertile must use medically acceptable contraceptive throughout treatment period 3 month follow cessation treatment oxaliplatin . Subjects must make aware , enter trial risk become pregnant fathering child Corticotherapy except antiemetic purpose Pregnant breast feed woman ( Documentation negative pregnancy test must available premenopausal woman intact reproductive organ ) Uncontrolled congestive heart failure angina pectoris , hypertension arrhythmia Uncontrolled persistent hypercalcemia History significant neurologic psychiatric disorder Vater ampulomas biliary tract adenocarcinoma Other non cure malignancies The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>